Medical/Pharmaceuticals
OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies
SEOUL, South Korea, April 3, 2025 /PRNewswire/ -- OSR Holdings, Inc. ("OSR") (NASDAQ: OSRH), a global healthcare company focused on advancing innovative therapies, today announced that it has entered into a Common Stock Purchase Agreement with White Lion GBM Innovation Fund ("Innovation Fund")...
2025-04-03 19:30
6359
Farrer Park Hospital and Alliance Healthcare Group Limited Forge Strategic Partnership to Enhance Patient Care and Promote Sustainable Healthcare Models
SINGAPORE, April 3, 2025 /PRNewswire/ -- Farrer Park Hospital and Alliance Healthcare Group Limited (Alliance) had on27 March 2025 entered into a strategic partnership to drive innovation in healthcare delivery, strengthen collaboration between providers, payers, and physicians, and improve patie...
2025-04-03 17:00
3123
Fangzhou Designated as a 2024 National High-Tech Enterprise Amid Record Growth
BEIJING, April 3, 2025 /PRNewswire/ -- Beijing Fangyixing Information Technology Co., Ltd. ("Fangyixing"), a subsidiary ofChina's leading Internet healthcare solutions provider Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), has been certified as a 2024 National High-Tech Enterprise, sol...
2025-04-03 15:25
4129
IRBM Expands Functional Genomics Platform to Strengthen Early Drug Discovery
De-Risking Target Validation with Data-Driven Genomic Insights ROME, April 3, 2025 /PRNewswire/ -- IRBM, an integrated Contract Research Organization (CRO) specializing in preclinical drug discovery, has established a comprehensive Functional Genomics Platform to support genetic target identific...
2025-04-03 07:45
4626
LBB Specialties Partners with Kerry Group to Launch Pharmaceutical Lactose to the Life Sciences Market
NORWALK, Conn., April 3, 2025 /PRNewswire/ -- LBB Specialties (LBBS), a leader inspecialty chemicals and ingredient distribution in North America, is pleased to announce a new partnership with Kerry Group, a world leading taste and nutrition partner for the food, beverage, and pharmaceutical mark...
2025-04-03 01:30
2668
Mabwell Announces NMPA Approval to Initiate Clinical Trial of novel B7-H3-targeting ADC for Advanced Solid Tumors in Combination with PD-1 Inhibitor
SHANGHAI, April 2, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel B7-H3-targeting ADC (R&D code: 7MW3711) has been approved by the NMPA to enter Phase Ib/II clinical trial in combination with a PD-1 Inhibitor, with...
2025-04-02 22:00
3142
NCCN 2025 Annual Conference Illustrates the Critical Impact of Cancer Research on Improving Lives
The National Comprehensive Cancer Network celebrated its 30th anniversary with a series of presentations on cancer care practice changes—in both treatment and administration—plus new research, and other changes for the oncology workforce and the patients they serve. ORLANDO, Fla., April 2, 2025 ...
2025-04-02 21:06
2358
"miraDry Releases the First Ever Sweat Scope Report, Shedding Light on Underarm Sweat and Odor in Menopause"
NEWPORT BEACH, Calif., April 2, 2025 /PRNewswire/ -- Today, miraDry, Inc., in partnership with the International Hyperhidrosis Society (IHhS), announced the results of a landmark study focusing on a rarely discussed aspect of menopause: underarm sweat and odor. The study, titled "Sweat Scope: The...
2025-04-02 21:00
2670
FWD Hong Kong forms partnerships to launch "Talk2Me Peer Supporter Training Certificate Programme" and "JA SparktheDream Wellness Workshop" to promote youth mental health
HONG KONG, April 2, 2025 /PRNewswire/ -- Youth mental health is one of the most widely discussed social issues inHong Kong. This underscores the need for mental health support for youth. In response, FWD Hong Kong ("FWD") has collaborated with two non-profit organisations,KELY Support Group and J...
2025-04-02 19:12
4084
Senhwa Biosciences Announces Positive Clinical Data from Phase 1/Expansion Trial of Silmitasertib (CX-4945) in the Treatment of Basal Cell Carcinoma
Basal Cell Carcinoma CSR Highlights * CX-4945 Monotherapy: Progression-free survival (PFS) exceeded 21 months in two patients. * Optimal Treatment Response: Three patients achieved partial response (PR), while ten patients had stable disease (SD). * Tolerability & Disease Control Rate: Sho...
2025-04-02 15:56
2688
Fosun International 2024 Annual Results Presentation: Aiming for RMB10 Billion in Future Industrial Operation Profit
HONG KONG and SHANGHAI, April 2, 2025 /PRNewswire/ -- On 1 April 2025, Fosun International Limited (HKEX stock code: 00656, "Fosun International"), together with its subsidiaries ("Fosun" or the "Group") held its 2024 annual results presentation inShanghai. The results presentation was attended b...
2025-04-02 13:51
4974
Hanmi Pharmaceutical's 'Gugutams' to be Launched in Mexico as 'Aditams', Marking the Start of Full-Scale Latin America Expansion
Hanmi Pharm Begins Local Sales of Urological Product 'Aditams' in Mexico with Partner 'Laboratorios Silanes' Launch completed in February, Hanmi Pharm's Third Product to Enter Latin America Aditams, The First Urological Combination Drug for OPG and ED Exported to Mexico SEOUL, South Korea, Ap...
2025-04-02 12:17
2560
Human Frontier Science Program: Research Grants Awarded to 104 of the Most Pioneering Scientists from 30 Nations
STRASBOURG, France, April 2, 2025 /PRNewswire/ -- To pioneer new frontiers in
life science research, the Human Frontier Science Program has awarded 104 of
the world's most ingenious scientists from 30 nations with 2025 HFSP Research
Grants and the first round of the new Accelerator Grants.
2025-04-02 08:10
2513
Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma
MELBOURNE, Australia, April 2, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that a first patient has been dosed in the Phase 1 ZOLAR[1] trial of TLX300-CDx (89 Zr-olaratumab) in patients with advanced, metastatic soft tissue sarcoma...
2025-04-02 03:30
2833
Yingli Pharma Announces Successful End-of-Phase 2 Meeting with FDA and Clearance of Global Multi-center Phase 3 Registration Study Design of Linperlisib for the Treatment of Relapsed and/or Refractory Peripheral T-cell Lymphoma
SAN FRANCISCO, April 1, 2025 /PRNewswire/ -- Shanghai Yingli Pharmaceutical Co., Ltd. (Yingli Pharma), a clinical stage biotechnology company developing oral small molecule drugs for cancer, metabolic, and immune diseases, announced today that it has received clearance from the US Food and Drug A...
2025-04-01 22:00
2962
Senior Vice President at United Imaging Inducted to the AIMBE College of Fellows
HOUSTON, April 1, 2025 /PRNewswire/ -- United Imaging, a global manufacturer of modern medical imaging technology, is proud to announce thatLingzhi (Lance) Hu, Ph.D., Senior Vice President and Chief Technology Officer of United Imaging Research at United Imaging, has been inducted into the 2025 C...
2025-04-01 21:00
2168
Peijia Medical collaborates with dsm-firmenich to create groundbreaking innovative medical device products
SUZHOU, China, April 1, 2025 /PRNewswire/ -- Today, April 1st, Peijia Medical Technology (Suzhou) Co., Ltd. held a strategic innovation cooperation signing ceremony and a press conference to announce the research and development achievements of polymer heart valves using ultra-high molecular weig...
2025-04-01 20:00
2760
Dizal Announces DZD8586 and DZD6008 Presentations at 2025 ASCO Annual Meeting
SHANGHAI, April 1, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that results of its investigational drug candidatesDZD8586 and DZD6008, have been selected for pr...
2025-04-01 18:18
2589
PeptiGrowth Inc. is Launching a Novel Synthetic Peptide: KGF alternative peptide (FGFR2b agonist)
TOKYO, April 1, 2025 /PRNewswire/ -- PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Junichiro Ishizuka) has successfully developed a novel synthetic peptide called "KGF alternative- peptide (FGFR2b agonist)" which is functionally equivalent to recombinant keratinocyte growth factor ...
2025-04-01 14:30
2309
ECHO IQ SIGNS STRATEGIC PARTNERSHIP AND INTEGRATION AGREEMENTS WITH SCIMAGE AND MEDAXIOM TO EXPAND ECHOSOLV AS ACROSS 36 US CARDIOLOGY NETWORKS
* EchoSolv AS will be fully integrated into ScImage's medical workflow platform, facilitating streamlined deployment within MedAxiom's hospital and cardiology networks. * ScImage is a nationally recognised Cloud and integrated workflow management platform, with over 1,200 users, specialisin...
2025-04-01 13:39
2666
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 319 media titles]
2026-01-23 11:03
Agoda Launches Agoda Impact Lab at ASEAN Tourism Forum
[Picked up by 318 media titles]
2026-01-29 15:06
Agoda Launches Open-Source API Agent to Simplify MCP Server Integrations
[Picked up by 309 media titles]
2026-01-27 13:00
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 307 media titles]
2026-01-23 09:00Nokia Strengthens Edge AI Capabilities Through Strategic Collaboration with Blaize on Hybrid Inference Solutions Across Asia Pacific Regions
[Picked up by 294 media titles]
2026-01-27 18:00
Most Read
Robo.ai Partners with The Ghazi Group to Power AI Compute Infrastructure Growth in MENA and Southeast Asia
2026-01-23 19:02
8500
